about
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentThe use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.Brain single photon emission computed tomography: technological aspects and clinical applications.In vivo monitoring of Staphylococcus aureus biofilm infections and antimicrobial therapy by [18F]fluoro-deoxyglucose-MicroPET in a mouse model.Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.Ventricular wall granulations and draining of cerebrospinal fluid in chronic giant hydrocephalus.Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.Cortical atrophy and language network reorganization associated with a novel progranulin mutation.Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Enhanced GDNF expression in dopaminergic cells of monkeys grafted with carotid body cell aggregates.Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.Transient posterior encephalopathy induced by chemotherapy in children.Decreased carbon-11-flumazenil binding in early Alzheimer's disease.Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine.Quantitative estimation of the primary auditory cortex in human brains.New MRI, 18F-DOPA and 11C-(+)-alpha-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: advantages to improve PET quantification.The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis.Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis.PET optimization for improved assessment and accurate quantification of 90Y-microsphere biodistribution after radioembolization.Emerging clinical issues and multivariate analyses in PET investigations.Liver disease induced by radioembolization of liver tumors: description and possible risk factors.Metabolic patterns in prion diseases: an FDG PET voxel-based analysis.Clinical and neuroimaging characteristics of 14 patients with prionopathy: a descriptive study.A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.Monitoring the Effect of Immunotherapy in Autoimmune Limbic Encephalitis Using 18F-FDG PET.Functional neuroimaging studies in asymmetric hearing loss.Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease.Sustained attention in a counting task: normal performance and functional neuroanatomy.Functional neuroanatomy of sustained attention in schizophrenia: contribution of parietal cortices.Unilateral periodic limb movements during sleep in corticobasal degeneration.Activation of the brainstem but not of the hypothalamus in hemicrania continua without autonomic symptoms.Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.Successful thalamic deep brain stimulation for orthostatic tremor.[Functional neuroimaging in the diagnosis of patients with Parkinsonism: Update and recommendations for clinical use].Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.Brain PET imaging optimization with time of flight and point spread function modelling.[Contribution of time of flight and point spread function modeling to the performance characteristics of the PET/CT Biograph mCT scanner].Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors.Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.
P50
Q28083433-40200910-CF12-4D1F-9D0E-B4BD182BDD33Q31156299-91BA0510-04AE-4E4D-98B5-4FE62D5C84B6Q34014036-26CBE0C6-9FD4-4FDB-ADB8-B2D7A459CD60Q34596570-49B07254-3150-4388-A766-E77FF7498EF5Q34621197-C11493B2-6AD1-4EEC-ABA9-E3E96D85654AQ34940640-3E5C67F3-B514-43A4-A288-0DC15C0998F0Q37721132-818EAFCA-D773-4CDE-9239-AAF88A111190Q38385539-CDE7E072-B93C-4547-8FE4-EEEAA909C75CQ38534611-A52A9F9E-9F42-41DC-8109-ECC3B5C36C90Q38815396-F6BEF375-CB8B-4D8F-95EE-789FD421E539Q39618525-079EC499-6FCD-40C2-B23A-E90DA1CAE4F8Q43123132-71AFD0CB-E078-4973-8E3A-E63DA3EA8449Q43557661-D50DF992-1CCD-4522-9FB0-E179E41DACEAQ44014493-A440698C-A11D-4908-B18C-1407A421BF70Q44414803-D546049E-F96B-437C-A5D0-D6794305DF38Q44842169-603D03B7-F4D4-45A4-B5AF-CCED9E4B06ABQ46021600-A7881E4A-8988-4454-B025-A7C3552530C5Q46106323-40E5AEF9-FC52-4F48-A323-878E08490F53Q46327044-ACFD9975-5936-44C5-8975-996E6148283AQ46667135-D49F9FBD-F8BF-4551-BEBB-EEABEF8E71D9Q47703976-EE1D3CCA-A86D-4D8C-9FDB-1C4329AB5DE2Q47925759-D758551B-E122-454D-AB06-3BED14882DBDQ47967854-BE9EC52E-F747-45A7-B9B2-CC163E328993Q48122909-52779D89-F2B5-4B48-B5D6-AD156DC13213Q48132965-D0710FFC-FD32-4FD1-96DB-466DF289686CQ48138961-7439BC69-3DF3-444B-8764-AF815CA1A19EQ48166286-DDA2BB32-17C6-439D-ABC6-670717219FA4Q48416681-D226F5AC-6E00-456C-9DB1-81CB219039D4Q48426061-E508FC89-55C0-4B0D-B131-6A12BAB32828Q48479005-3C1C3078-2160-4369-8B15-0F021E1F1615Q48676132-BC47CF2E-018B-4DE6-9394-263680B741ADQ48707569-0CDDB1AA-93A0-4E73-89A0-42E44F239A53Q48969798-FAE500CD-43C5-4FE0-9409-D40A4DD0261DQ49021359-A7C10F90-CA90-4B5D-8866-C86F21A5CD23Q50473828-C9CD59F1-85D5-4B11-B5F4-0DDB88ECBC0AQ50479860-D92F11EB-C3C5-4174-9587-147ACD3AD00EQ50870726-A866FF00-0306-44AD-A90C-A7D9BE9F111EQ53140956-62BF53A2-D073-43DF-BB42-B47FD0558945Q53328480-85DF2D78-16C3-4AE5-8734-13FA98602A48Q53397742-C06B7A03-9DA8-40E9-90CC-3708DB14E9EF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Javier Arbizu
@ast
Javier Arbizu
@en
Javier Arbizu
@es
Javier Arbizu
@nl
Javier Arbizu
@sl
type
label
Javier Arbizu
@ast
Javier Arbizu
@en
Javier Arbizu
@es
Javier Arbizu
@nl
Javier Arbizu
@sl
prefLabel
Javier Arbizu
@ast
Javier Arbizu
@en
Javier Arbizu
@es
Javier Arbizu
@nl
Javier Arbizu
@sl
P1053
H-9255-2017
P106
P21
P31
P3829
P496
0000-0002-8370-5510